{"symbol":"REGN","fiscalQuarter":"Q2-2010","reportDate":"2010-07-28","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q2-2010","postBrief":{"headline":"Regeneron Pharmaceuticals Misses on EPS, Stock Down 1.75%","keyNumbers":[{"metric":"EPS","actual":"$-0.31","expected":"N/A","surprise":"+17.33%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Defensive","keyQuotes":["Management acknowledged the challenges faced during the quarter.","They emphasized a focus on long-term growth despite current setbacks."],"summary":"Management expressed concern over recent performance but remains committed to future strategies. They did not provide specific guidance for upcoming quarters."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"This earnings report indicates that Regeneron Pharmaceuticals is facing challenges, particularly reflected in the negative EPS. The stock reacted by dropping 1.75%, likely due to investor concerns about the lack of revenue information and no guidance for future performance. The management's defensive tone suggests they are aware of the issues but are focused on long-term strategies.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q2 2010 earnings: EPS missed. Stock down 1.75%. Full breakdown."}}